Core Insights - Cencora, Inc. (COR) has agreed to merge its subsidiary MWI Animal Health with Covetrus, valuing MWI at an enterprise value of $3.5 billion [1][9][10] - The merger aims to enhance operational efficiency and growth in the animal health ecosystem by combining MWI's distribution capabilities with Covetrus' technology [2][12] Company Summary - The transaction allows Cencora to unlock capital from MWI while retaining a 34.3% equity stake in the combined entity, which strengthens its balance sheet with $1.25 billion in cash, $800 million in preferred equity, and $1.45 billion in common equity [4][11] - Cencora's market capitalization stands at $70 billion, reflecting its significant position in the market [7] - The merger is expected to create a more integrated platform that improves access and innovation in the animal health market [12][13] Industry Summary - The global animal health market is projected to grow from $62.89 billion in 2024 to $112.33 billion by 2030, with a compound annual growth rate (CAGR) of 10.46% [15] - Key drivers of market growth include increased spending on animal healthcare, the integration of artificial intelligence, and rising concerns about animal diseases and zoonotic infections [16] - Cencora's recent fiscal first-quarter results showed mixed performance, with earnings exceeding estimates and revenues meeting expectations, supported by growth in healthcare solutions and specialty products [17]

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Bank of America 2026 Virtual Animal Health Summit. Chief Financial Officer, Glenn David; Chief Operating Officer, Larry Miller and Executive Vice President, Corporate Strategy and CEO designate Daniel Bendheim will address financial analysts and investors on Thursday, February 26, 2026, at 10:45 AM ET. The live audio presentation will be available on the Phibro Animal Healt. ...

Core Viewpoint - ImmuCell Corporation is set to report its unaudited financial results for the quarter and year ended December 31, 2025, on March 4, 2026, with a conference call scheduled for the following morning to discuss these results [1][2][3]. Financial Reporting - The company anticipates no changes to the preliminary sales results disclosed on January 8, 2026, for the quarter and year ended December 31, 2025 [3]. - ImmuCell plans to file its Annual Report on Form 10-K on or before March 31, 2026 [3]. Company Overview - ImmuCell Corporation focuses on developing, manufacturing, and marketing products that enhance cattle health and productivity, including its product First Defense, which provides Immediate Immunity™ to newborn dairy and beef calves [4].

Core Viewpoint - Phibro Animal Health Corporation (NASDAQ:PAHC) is recognized as one of the seven cheap pharmaceutical stocks to consider for investment, particularly noted for its strong operational performance and positive financial outlook [1][2]. Financial Performance - For the fiscal second quarter ending December 31, 2025, Phibro reported a 21% increase in net sales to $373.9 million and a rise in net income to $27.5 million [4]. - Adjusted EBITDA increased by 41% to $68.1 million, while adjusted diluted EPS rose by 58% to $0.87 [4]. - The company has updated its fiscal 2026 net sales estimates to between $1.45 billion and $1.50 billion, with adjusted EBITDA projected between $245 million and $255 million, reflecting improved operating momentum [5]. Analyst Ratings - Morgan Stanley raised its price target for PAHC from $45 to $49, maintaining an Equal Weight rating, citing strong operational performance and effective execution in the Animal Health segment [3]. - The upgrade was influenced by significant margin expansion, a favorable fiscal 2026 forecast, and a profit beat in the second quarter [3].

PetVivo (OTCPK:PETV) Q3 2026 Earnings call February 17, 2026 05:00 PM ET Company ParticipantsGarry Lowenthal - CFOJohn Dolan - Chief Business Development Officer and General CounselJohn Lai - CEOConference Call ParticipantsNone - AnalystJohn DolanGood afternoon, everyone. Thank you for joining us today to discuss our results for our third quarter and first nine months of fiscal 2026, ended December 31, 2025. Hosting our call today is our Chief Executive Officer, John Lai, and our Chief Financial Officer, Ga ...

PetVivo (OTCPK:PETV) Q3 2026 Earnings call February 17, 2026 05:00 PM ET Company ParticipantsGarry Lowenthal - CFOJohn Dolan - Chief Business Development Officer and General CounselJohn Lai - CEOConference Call ParticipantsNone - AnalystJohn DolanGood afternoon, everyone. Thank you for joining us today to discuss our results for our third quarter and first nine months of fiscal 2026, ended December 31, 2025. Hosting our call today is our Chief Executive Officer, John Lai, and our Chief Financial Officer, Ga ...

PetVivo (OTCPK:PETV) Q3 2026 Earnings call February 17, 2026 05:00 PM ET Speaker1Good afternoon, everyone. Thank you for joining us today to discuss our results for our third quarter and first nine months of fiscal 2026, ended December 31, 2025. Hosting our call today is our Chief Executive Officer, John Lai, and our Chief Financial Officer, Garry Lowenthal, as well as myself, John Dolan, PetVivo's Chief Business Development Officer and General Counsel. Following our remarks, we'll open the call to your que ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of 山東信得科技股份有限公司 Shandong Sinder Technology Co., Ltd. (A joint stock company incorporated in the People's Republic of C ...

Board of Directors Update - Elanco Animal Health Incorporated announced that R. David Hoover and Deborah Kochevar will not stand for re-election at the 2026 Annual Meeting of Shareholders in May [1] - R. David Hoover, the founding Chairman, is retiring after joining the Board in September 2018, playing a crucial role during the company's IPO and initial years as a public entity [1] - Dr. Deborah Kochevar, who joined the Board in March 2019, is also concluding her service, having led the Innovation, Science and Technology committee [1] Leadership Contributions - Lawrence E. Kurzius, Chairman of the Board, praised Hoover's foundational leadership and strategic direction during Elanco's transformation into an independent company [1] - Jeff Simmons, Elanco President and CEO, credited Hoover's insights for positioning Elanco as a global leader and emphasized the company's strong future [1] - Kochevar's expertise in veterinary medicine was highlighted as critical for supporting Elanco's innovation pipeline and maintaining a culture of scientific excellence [1] Future Board Composition - Following the departures, the Board will consist of nine directors, indicating a streamlined governance structure [1]

Core Viewpoint - Zoetis reported strong fourth-quarter results that exceeded expectations, leading to a positive outlook for fiscal 2026, which has boosted investor sentiment [1][2] Financial Performance - The company achieved adjusted earnings per share (EPS) of $1.48 for the fourth quarter, surpassing analyst estimates of $1.40, driven by stronger-than-expected revenue and gross margins [1] - For fiscal 2026, Zoetis projected adjusted EPS in the range of $7.00 to $7.10, with the midpoint exceeding Wall Street's consensus estimate of $6.80 [2] Revenue Outlook - Revenue for 2026 is expected to be between $9.825 billion and $10.025 billion, modestly exceeding the consensus projection of $9.914 billion [2] Investor Sentiment - The solid quarterly performance and forward guidance have positively influenced investor sentiment, despite some analysts raising concerns about the composition of the earnings beat [2]